605. Efficacy of a novel bis-indole antimicrobial compound in preventing catheters colonization and device-associated infection in a rabbit model
Session: Poster Abstract Session: Novel Antimicrobial Agents
Friday, October 21, 2011
Room: Poster Hall B1
Background: At least 200 thousand cases of catheter-related bloodstream infection occur each year in the US, and almost one-third affect critically ill patients. The success of existing antimicrobial-treated vascular catheters in combating these infections is limited, partly, due to the lack of antimicrobial activity against sessile organisms. In this in-vivo study, we assessed the ability of vascular catheters coated with a novel bis-amidine antimicrobial agent (MBX1631), which has an affinity for the minor groove of bacterial DNA, against catheter colonization and catheter-associated infection. 

Methods: One-cm segments of sterile MBX1631-coated and uncoated polyurethane central venous catheters were subcutaneously implanted in the back of rabbits. Each catheter segment was then inoculated with 103 cfu of Staphylococcus aureus, and the incisions made for implantation were sutured. Catheter segments were removed aseptically after one week and cultured quantitatively. Swab cultures from soft tissue surrounding the implanted device were also cultured to assess device-associated infection. The mean colony counts grown from catheter cultures were compared between MBX1631-coated and uncoated catheter segments. Furthermore, the frequency of catheter colonization and catheter-associated infection were compared between the two groups.

Results: Catheters coated with MBX1631 were significantly less colonized than uncoated catheters (P <002). Furthermore, the frequencies of catheter colonization and catheter-associated infection were significantly lower (P <0.001 and P<0.005, respectively) with MBX-1631-coated catheter segments compared to uncoated control catheter segments.

Conclusion: MBX1631-coated vascular catheters are less likely to become colonized with Staphylococcus aureus than uncoated catheters. These in-vivo results suggest that treatment of catheters with MBX1631 may potentially protect against catheter colonization and potential subsequent catheter-associated infection.

Subject Category: A. Antimicrobial agents and Resistance

Mohammad D. Mansouri, 1, Timothy Opperman2, John D. Williams2 and Rabih O. Darouiche1, (1)Baylor College of Medicine, Houston, TX, (2)Microbiotix, Inc., Worcester, MA


M. D. Mansouri, Microbiotix, Inc.: I am the co-inventor a patent, assigned to my employer, Baylor College of Medicine, that describes the coating of catheters with the novel compound, developed by Microbiotix. Currently, there is no licensing activity., Educational grant and Research grant

T. Opperman, Microbiotix, Inc: Employee, Salary

J. D. Williams, Microbiotix, Inc.: Employee, Salary

R. O. Darouiche, Microbiotix, Inc.: I have patent that describes the use of certain methods for coating devices. I have assigned these patents to my employer Baylor College of Medicine., Research grant

Findings in the abstracts are embargoed until 12:01 a.m. EST Thursday, Oct. 20 with the exception of research findings presented at IDSA press conferences.